AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MIAMI BEACH -- Gestational exposure to azithromycin was not associated with an increased risk above baseline for major fetal anomalies in a prospective, controlled trial of 369 pregnant women.
The antibiotic had a safety profile comparable to the profiles of other nonteratogenic agents.
The results suggest that the drug may be a good first-line choice for some infections in pregnancy, particularly among traditionally noncompliant populations, because of its demonstrated efficacy and simple one-dose regimen, Moumita Sarkar reported in a poster presentation at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.
To…